Yoshimitsu Yura
Overview
Explore the profile of Yoshimitsu Yura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahara K, Ouchi N, Takikawa T, Ozaki Y, Fang L, Kawanishi H, et al.
Physiol Rep
. 2025 Jan;
13(3):e70135.
PMID: 39887648
Chronic kidney disease is a life-threatening disease worldwide. PPARα is a crucial transcriptional regulator of lipid metabolism and inflammation. Here, we examine whether a novel selective PPARα modulator, pemafibrate modulates...
2.
Evans M, Chavkin N, Sano S, Sun H, Sardana T, Ravi R, et al.
Front Cell Neurosci
. 2025 Jan;
18:1487867.
PMID: 39742155
Introduction: Recent work has revealed that clonal hematopoiesis (CH) is associated with a higher risk of numerous age-related diseases, including ischemic stroke, however little is known about whether it influences...
3.
Yoshida T, Yoshida S, Inukai K, Kato K, Yura Y, Hattori T, et al.
FASEB J
. 2024 Nov;
38(22):e70192.
PMID: 39556326
Protein phosphorylation, controlled by protein kinases, is central to regulating various pathophysiological processes, including cardiac systolic function. The dysregulation of protein kinase activity plays a significant role in the pathogenesis...
4.
Wang Y, Sano S, Yura Y, Ke Z, Sano M, Oshima K, et al.
JCI Insight
. 2024 Nov;
9(21).
PMID: 39513360
No abstract available.
5.
Yoshida S, Yoshida T, Inukai K, Kato K, Yura Y, Hattori T, et al.
Nat Commun
. 2024 Sep;
15(1):7638.
PMID: 39266515
Chronic fibrotic tissue disrupts various organ functions. Despite significant advances in therapies, mortality and morbidity due to heart failure remain high, resulting in poor quality of life. Beyond the cardiomyocyte-centric...
6.
Polizio A, Marino L, Min K, Yura Y, Rolauer L, Cochran J, et al.
Circ Res
. 2024 Sep;
135(9):933-950.
PMID: 39234670
Background: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver...
7.
Horitani K, Chavkin N, Arai Y, Wang Y, Ogawa H, Yura Y, et al.
Nat Cardiovasc Res
. 2024 Aug;
3(3):343-355.
PMID: 39183958
Heart failure affects millions of people worldwide, with men exhibiting a higher incidence than women. Our previous work has shown that mosaic loss of the Y chromosome (LOY) in leukocytes...
8.
Hiraiwa H, Yura Y, Okumura T, Murohara T
Heart Fail Rev
. 2024 Jul;
29(5):1049-1063.
PMID: 38985383
Improvements in therapies for heart failure with preserved ejection fraction (HFpEF) are crucial for improving patient outcomes and quality of life. Although HFpEF is the predominant heart failure type among...
9.
Cochran J, Yura Y, Thel M, Doviak H, Polizio A, Arai Y, et al.
Circulation
. 2023 Sep;
148(15):1165-1178.
PMID: 37681311
Background: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse...
10.
Gladyshev V, Kritchevsky S, Clarke S, Cuervo A, Fiehn O, de Magalhaes J, et al.
Nat Aging
. 2023 Feb;
1(12):1096-1106.
PMID: 36846190
Cellular metabolism generates molecular damage affecting all levels of biological organization. Accumulation of this damage over time is thought to play a central role in the aging process, but damage...